Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3664-3674

  Gubbins, Paul O ^a   Amsden, Jarrett R ^b   McConnell, Scott A ^a,d   Anaissie, Elias J ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b BUTLER UNIVERSITY   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B LIPID COMPLEX; CREATININE; ELECTROLYTE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS; BIOPSY; CANDIDA; CHEEK MUCOSA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FEMALE; FUNGAL STRAIN; HUMAN; HUMAN TISSUE; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INJECTION SITE REACTION; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION;

ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION;

EID: 70349144924     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01448-08     Document Type: Article

References (33)

1. Adler-Moore, J. P., J. A. Olsen, and R. T. Proffitt. 2004. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis. J. Antimicrob. Chemother. 54:1096-1102.
2. Andes, D., T. Stamsted, and R. Conklin. 2001. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob. Agents Chemother. 45:922-926.
3. Andes, D. 2004. Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Curr. Opin. Infect. Dis. 17:533-540.
4. Andes, D., N. Safdar, K. Marchillo, and R. Conklin. 2006. Pharmacokineticpharmaco-dynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob. Agents Chemother. 50:674-684.
5. Bekersky, I., R. M. Fielding, D. E. Dressler, J. W. Lee, D. N. Buell, and T. J. Walsh. 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46:828-833.
6. Bekersky, I., R. M. Fielding, D. E. Dressler, J. W. Lee, D. N. Buell, and T. J. Walsh. 2002. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 46:834-840.
7. 14C-cholesterol-labeled AmBisome to healthy volunteers. J. Clin. Pharmacol. 41:963-971.
8. Boswell, G. W., I. Bekersky, D. Buell, R. Hiles, and T. J. Walsh. 1998. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob. Agents Chemother. 42:263-268.
9. Chang, C. W., L. Barber, C. Ouyang, M. B. Bally, and T. D. Madden. 1997. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br. J. Cancer 75:169-177.
10. Davies, B., and T. Morris. 1993. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095.
11. de Marie, S., R. Janknegt, and I. A. Bakker-Woudenberg. 1994. Clinical use of liposomal and lipid-complexed amphotericin B. J. Antimicrob. Chemother. 33:907-916.
12. Fielding, R. M. 2001. Relationship of pharmacokinetically-calculated volumes of distribution to the physiologic distribution of liposomal drugs in tissues: implications for the characterization of liposomal formulations. Pharm. Res. 18:238-242.
13. Fielding, R. M., R. O. Lewis, and L. Moon-McDermott. 1998. Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome). Pharm. Res. 15:1775-1781.
14. Garcia, A., J. P. Adler-Moore, and R. Proffitt. 2000. Single-dose AmBisome (liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis. Antimicrob. Agents Chemother. 44:2327-2332.
15. Goodwin S. D., J. D. Cleary, C. A. Walawander, J. W. Taylor, and T. H. Grassela, Jr. 1995. Pretreatment regimens for adverse effects related to infusion of amphotericin B. Clin. Infect. Dis. 20:755-761.
16. Groll, A., S. C. Piscitelli, and T. J. Walsh. 1998. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. 44:343-500.
17. Groll, A. H., N. Giri, V. Petraitis, R. Petraitiene, M. Candelario, J. S. Bacher, S. C. Piscitelli, and T. J. Walsh. 2000. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182:274-282.
18. Gubbins, P. O., S. R. Penzak, S. Polston, S. A. McConnell, and E. J. Anaissie. 2002. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 22:961-971. (Pubitemid 34831291)
19. Klepser, M. E., E. J. Wolfe, R. N. Jones, C. H. Nightingale, and M. A. Pfaller. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41:1392-1395.
20. Klepser, M. E., E. J. Wolfe, and M. A. Pfaller. 1998. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. J. Antimicrob. Chemother. 41:397-401.
21. Lawrence, R. M., P. D. Hoeprich, F. A. Jagdis, N. Monji, A. C. Huston, and C. P. Schaffner. 1980. Distribution of doubly radiolabelled amphotericin B methyl ester and amphotericin B in the non-human primate Maccaca mulatta. J. Antimicrob. Chemother. 6:241-249.
22. Lewis, R. E., N. D. Albert, and D. P. Kontoyiannis. 2008. Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 52:4178-4180.
23. Lewis, R. E., L. Guangling, J. Hou, G. Chamilos, R. A. Prince, and D. P. Kontoyiannis. 2007. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung activation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 51:1253-1258.
24. Mehta, P., A. Vinks, A. Flipovich, G. Vaughn, D. Fearing, C. Sper, and S. Daives. 2006. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol. Blood Marrow Transplant. 12:235-240.
25. Mouton, J. W., U. Theuretzbacher, W. A. Craig, P. M. Tulkens, H. Derendorf, and O. Cars. 2008. Tissue concentrations: do we ever learn? J. Antimicrob. Chemother. 61:235-237.
26. Müller, M., A. dela Pena, and H. Derendorf. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48:1441-1453.
27. Newman, M. S., G. T. Colbern, P. K. Working, C. Engbers, and M. A. Amantea. 1999. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 43:1-7.
28. Olson, J. A., J. P. Adler-Moore, J. Schwartz, G. M. Jensen, and R. T. Proffitt. 2006. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob. Agents Chemother. 50:2122-2131.
29. Ostro, M. J., and P. R. Cullis. 1989. Use of liposomes as injectable drug delivery systems. Am. J. Hosp. Pharm. 46:1576-1587.
30. Smith, P. J., J. A. Olson, D. Constable, J. Schwartz, R. T. Profitt, and J. P. Adler-Moore. 2007. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J. Antimicrob. Chemother. 59:941-951.
31. van Etten, E. W., S. V. Snijders, W. van Vianen, and I. A. Bakker-Woudenberg. 1998. Superior efficacy of liposomal amphotericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic mice. Antimicrob. Agents Chemother. 42:2431-2433.
32. Walsh, T. J., J. L. Goodman, P. Pappas, I. Bekersky, D. N. Buell, M. Roden, J. Barrett, and E. J. Anaissie. 2001. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45:3487-3496.
33. Walsh, T. J., V. Yeldandi, M. McEvoy, C. Gonzalez, S. Chanock, A. Freifeld, N. I. Seibel, P. O. Whitcomb, P. Jarosinski, G. Boswell, I. Bekersky, A. Alak, D. Buell, J. Barret, and W. Wilson. 1998. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. 42: 2391-2398.